The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo
Published version of a preprint
Abstract
Well-differentiated/dedifferentiated liposarcomas (WD/DDLPS) are among the most common subtypes of soft tissue sarcomas. Conventional systemic chemotherapy has limited efficacy and novel therapeutic strategies are needed to achieve better outcomes for patients. The cyclin-dependent kinase 4 (CDK4) gene is highly amplified in more than 95% of WD/DDLPS. In this study, we explored the role of CDK4 and the effects of NVP-LEE011 (LEE011), a novel selective inhibitor of CDK4/CDK6, on a panel of human liposarcoma cell lines and primary tumor xenografts. We found that both CDK4 knockdown by siRNA and inhibition by LEE011 diminished retinoblastoma (RB) phosphorylation and dramatically decreased liposarcoma cell growth. Cell-cycle analysis demonstrated arrest at G0-G1. siRNA-mediated knockdown of RB rescued the inhibitory effects of LEE011, demonstrating that LEE011 decreased proliferation through RB. Oral administration of LEE011 to mice bearing human liposarcoma xenografts resulted in approximately 50% reduction in tumor (18)F-fluorodeoxyglucose uptake with decreased tumor biomarkers, including RB phosphorylation and bromodeoxyuridine incorporation in vivo. Continued treatment inhibited tumor growth or induced regression without detrimental effects on mouse weight. After prolonged continuous dosing, reestablishment of RB phosphorylation and cell-cycle progression was noted. These findings validate the critical role of CDK4 in maintaining liposarcoma proliferation through its ability to inactivate RB function, and suggest its potential function in the regulation of survival and metabolism of liposarcoma, supporting the rationale for clinical development of LEE011 for the treatment of WD/DDLPS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“alterations in expression of such cell cycle regulators, including cyclin E and p27Kip1, as well as D-type cyclins themselves, have been demonstrated in adaptation to CDK4/6 inhibition, potentially contributing to acquired resistance (108, 134-136).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [136]
In the citing paper
“some of these adaptations are reversible after drug removal suggesting, perhaps counter-intuitively, the potential value of intermittent dosing schedules for maintenance of cell cycle arrest.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [136]
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · cited 10×
“org Mol Cancer Ther; 13(9) September 2014 2189”
BackgroundInfluentialFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“A similar observation has been reported in studies with PD0332991 in other cancer types (28), wherein no cell death was observed in vitro, whereas in vivo treatment resulted in complete regressions in some tumormodels.”
ResultHarbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965 · cited 1×
“Deregulated expression of cyclin D has been shown to promote mitogen-independent proliferation as well as other cellular processes (9, 32).”
BackgroundPeng, X.-D., Xu, P.-Z., Chen, M.-L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., Coleman, K. G., et al. (2003) · Genes & Development · doi:10.1101/gad.1089403 · Cited by 826 · cited 1×
“Adipogenic differentiation was confirmed via Oil red O staining as previously described (24).”
MethodCyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778 · cited 1×
“amplification, or overexpression of CDK4 (11).”
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
“Among a variety of inhibitors, those with the highest degree of specificity for CDK4/CDK6 kinases include PD0332991 (palbociclib) [22], LY2835219 (abemaciclib) [137], and LEE011 (ribociclib) [138].”
Background
Metadata
- Authors
- Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., & Wagner, A. J.
- Affiliations
- 1Ludwig Center at Dana-Farber/Harvard, Harvard Medical School, Boston, Massachusetts.
- Harvard University (US)
- Johns Hopkins University (US)
- Novartis (Switzerland) (CH)
- Brigham and Women's Hospital (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2014-09-01
- Volume
- 13
- Issue
- 9
- Pages
- 2184-2193
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2157803976
- Cited by
- 114
- References
- 38
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 11 · 2021: 4 · 2020: 8 · 2019: 5 · 2018: 10 · 2017: 27 · 2016: 13 · 2015: 13
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- CDK4/6 inhibition, liposarcoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, CDK4 amplification, retinoblastoma protein phosphorylation, G0/G1 cell cycle arrest, tumor xenografts, soft tissue sarcoma, antiproliferative activity, tumor growth inhibition
- MeSH terms
- Administration, Oral, Animals, Body Weight, Cell Cycle, Cell Differentiation, Cells, Cultured, Female, Humans, Immunohistochemistry, Liposarcoma, Male, Mice, Nude, Neoplasm Transplantation, Phosphorylation, Retinoblastoma Protein, Gene Dosage, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0387
- The paper
- Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., & Wagner, A. J. (2014). Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.